A gene called NDRG1 may help drive blood vessel remodeling seen in chronic thromboembolic pulmonary hypertension (CTEPH) by shifting smooth muscle cells toward a scar-forming state, a study found. “NDRG1 and related key gene axes may serve as potential therapeutic targets for CTEPH,” researchers wrote. The study, “Single-cell transcriptomics…
News
While both Winrevair (sotatercept) and prostacyclin therapies are used to treat pulmonary arterial hypertension (PAH), a new study shows the two treatments appear to affect blood flow differently among PAH patients. When people with this rare type of pulmonary hypertension started prostacyclin treatment, resistance to blood flow in the…
Low blood levels of several oxygen‐sensing molecules are found in people with pulmonary arterial hypertension (PAH), and testing for them may be a useful noninvasive tool for helping make a PAH diagnosis, according to a new study. Specifically, levels of a protein subunit known as HIF-1alpha showed strong…
Subtle liver problems may contribute to the development of pulmonary arterial hypertension (PAH), suggesting complex communication between the lungs and liver along a so-called lung-liver axis, according to a study. Some people with PAH but no known liver disease showed signs of mild liver dysfunction, enhanced lung-related inflammatory processes,…
Corsair Pharma‘s experimental skin-worn patch designed to deliver treprostinil, an approved treatment for pulmonary arterial hypertension (PAH), appears to be working as intended, according to newly announced data from an early clinical trial in healthy volunteers. “These data support the potential of our transdermal [through-the-skin] platform as a…
Higher TAGLN2 gene activity may contribute to the development of pulmonary arterial hypertension (PAH), according to a new study. Using genetic analyses and experiments in animals, researchers identified two specific DNA sites that influenced TAGLN2 expression (activity) and PAH risk. These are two sites where a chemical mark called…
Risk factors for pulmonary hypertension (PH) in people receiving maintenance hemodialysis, a blood-filtering treatment used when kidney function is severely reduced, appear to change with age, according to a single-center study in China. Diabetes was a risk factor for PH in patients 60 or older. In younger patients, PH…
Note: This story was updated May 28, 2026, to clarify the indications for which Cereno Scientific’s experimental therapies are being developed. The company is advancing CS1 as a potential treatment for pulmonary arterial hypertension. The first participant has been dosed in a clinical trial testing the pharmacological properties of…
An experimental inhaled therapy called LAM-001 significantly reduced symptom severity for all patients who completed a small Phase 2a clinical trial for pulmonary hypertension with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension. “These findings are encouraging for patients and the broader pulmonary hypertension community and support continued development…
Using artificial intelligence (AI) analyses of clinical data from hundreds of patients, scientists have created a new system to calculate the risk of future clinical worsening in people with pulmonary arterial hypertension (PAH). “To our knowledge, this is the first study to use machine learning to leverage existing [electronic…
Using artificial intelligence (AI) and analyzing genetic data focused on two primary biochemical processes, a team of scientists in China has identified two genes that appear to play key roles in driving pulmonary arterial hypertension (PAH). Computer-based analyses suggest that these two genes, called ATP1B1 and HP, may be…
A new partnership aims to incorporate more patient perspectives into the development of medications for pulmonary hypertension (PH). Cereno Scientific will partner with PHA Europe & Global on a patient-centered drug design project. Patient-centered drug development enables people affected by a disease to contribute throughout the development…
